| Cat. No. |
Product Name |
Information |
| PC-42386 |
RG13022
EGFR inhibitor
|
RG13022 is a potent EGFR inhibitor that inhibits EGFR autophosphorylation with IC50 of 5 uM in cell-free assays. |
| PC-42383 |
RG14620
EGFR inhibitor
|
RG14620 is a potent EGFR inhibitor that inhibits EGFR autophosphorylation with IC50 of 4 uM in cell-free assays. |
| PC-42546 |
AV-412 free base
EGFR inhibitor
|
AV-412 free base (MP412) is a potent dual inhibitor of EGFR and ErbB2, inhibits EGFR/EGFR L858R/EGFR T790M/EGFR L858R, T790M/ErbB2 with IC50 of 1.5/0.5/0.8/2.3/19 nM respectively. |
| PC-42545 |
AV-412
EGFR inhibitor
|
AV-412 (MP 412) is a potent dual inhibitor of EGFR and ErbB2, inhibits EGFR/EGFR L858R/EGFR T790M/EGFR L858R, T790M/ErbB2 with IC50 of 1.5/0.5/0.8/2.3/19 nM respectively. |
| PC-45479 |
PD158780
EGFR inhibitor
|
PD158780 is a highly potent, selective, ATP binding site inhibitor of EGFR with IC50 of 8 nM. |
| PC-45995 |
Mutated EGFR-IN-1
EGFR inhibitor
|
Mutated EGFR-IN-1 is an analogue of AZD9291 that is a useful intermediate for the inhibitors design for mutated EGFR, such as L858R EGFR, Exonl9 deletion activating mutant and T790M resistance mutant. |
| PC-25021 |
Sevabertinib
HER2 inhibitor
|
Sevabertinib (BAY 2927088) is a potent, selective, reversible inhibitor of mutant epidermal growth factor receptors 2 (HER2), including HER2 exon 20 insertions and HER2 point mutations. |
| PC-24971 |
Pebezertinib
EGFR inhibitor
|
Pebezertinib (BLU-451, LNG-451) is a potent, CNS-penetrant, wild-type EGFR sparing inhibitor of EGFR exon 20 insertion mutations, as well as atypical (G719C, G719S, L861Q) and common EGFR mutants. |
| PC-24940 |
Genistein
Hsp90β inhibitor
|
Genistein (NPI 031L) is a soy isoflavone and multiple tyrosine kinases (e.g., EGFR, MKK4 (IC50=400 nM)) inhibitor, Genistein is a chemotherapeutic agent against different types of cancer. |
| PC-24922 |
EGFR-targeting peptide GE11
EGFR ligand
|
EGFR-targeting peptide GE11 is an epidermal growth factor receptor (EGFR)-specific ligand for active targeting of EGFR-overexpressing cancer cells, Conjugation of GE11 peptides to liposomal constructs enhances anti-tumor efficacies and specificities in laryngeal cancer cells. |
| PC-24741 |
HS-10375
EGFR C797S inhibitor
|
HS-10375 is a potent, selective EGFR C797S tyrosine kinase inhibitor, shows potent inhibitory activity against EGFR C797S mutations (Del19/T790M/C797S, L858R/T790M/C797S, Del19/C797S, and L858R/C797S), and common and/or T790M mutations (Del19, T790M, L858R/T790M, and Del19/T790M) with IC50 < 1.5 nM. |
| PC-24584 |
ELF3-MED23 interaction inhibitor YK1
ELF3-MED23 inhibitor
|
YK1 is a potent and selective PPI inhibitor for ELF3-MED23 with IC50 of 1.18 uM, 95 % inhibition at 10 uM, attenuates the HER2-mediated oncogenic signaling cascades. |
